Thelium Therapeutics
San Carlos, US · Founded 2019 · Delaware corporation
Founders & leadership
MB
Miro BrajenovicNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$3.1M disclosed across 1 round · 2022
▶$3.1MraisedMay 2022 · 10 investors · BiotechnologyRule 506(b)
▶$3.1MraisedMay 2022 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Miro BrajenovicExecutive Officer, Director
- Offering amount
- $18.1M
- Amount sold
- $3.1M
- First sale
- Apr 2022
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $795K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $224.3K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- How much funding has Thelium Therapeutics raised?
- Thelium Therapeutics has disclosed $3.1M raised across 1 round.
- Where is Thelium Therapeutics headquartered?
- Thelium Therapeutics is headquartered in San Carlos, US.